Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 Next › Last »

Prevision Policy Clips | FDA Tamps Down ALS Treatment Prospects With Unusual Public Statement

March 3, 2021

NASEM Vial Wastage Report Recommends Fixed Dosage Fix – FDA Should Require Fixed Doses In Trials; CMS Urged To Move Away From ASP In Part B

March 2, 2021

NASEM Advanced Manufacturing Report Calls For “More Timely” CDER Evaluations Of New Tech; Direct Funding For FDA’s Emerging Tech Program

March 2, 2021

Prevision Policy Clips | AstraZeneca/FibroGen Roxadustat Delayed Again: FDA Will Convene Advisory Committee

March 2, 2021

J&J COVID-19 Single-Shot Vaccine Authorized By FDA: Ongoing Two-Dose Study, Lower Efficacy In Older Age Group With Comorbidities Are Issues To Watch

March 1, 2021

Prevision Policy Clips | FDA Waiting On AstraZeneca, Novavax COVID-19 Vaccine U.S. Trials To Read Out Before Accepting EUA Request

March 1, 2021

RWE Studies For Regulatory Use: Sentinel May Lead On Development Of Outcome Algorithms Across Databases

February 26, 2021

Advisory Committee Tracker: Pfizer/Lilly Anti-NGF Therapy Tanezumab Will Test FDA’s Flexibility For Non-Opioid Pain Drugs

February 26, 2021

Prevision Policy Clips | Senate HELP Hearing on COVID Response Coming "Soon"

February 26, 2021

COVID-19 Observational Lessons: FDA/Duke Workshop Spotlights Tocilizumab Success, But Problems Gaining Acceptance

February 25, 2021

FDA Developing Guidances On RWE Studies For Regulatory Decisions; Duke/FDA Workshop Highlights Lessons Learned From Clinical Trial Replication Project

February 25, 2021

HHS Nominee Expands On Drug Pricing: Pledges “Bipartisan” Focus On Issue; Defends “March In” Letter On Remdesivir, But Stresses Extraordinary Circumstances

February 25, 2021

Prevision Policy Clips | Pharmaceutical Supply Chain Review By HHS: 100 Days To Generate Policy Recommendations

February 25, 2021

J&J One-Shot COVID-19 Vaccine: FDA Sees Lower Efficacy Balanced By Better Safety Profile, Sustained Efficacy Against South African Variant

February 24, 2021

Prevision Policy Clips | White House Will Order Review of Pharmaceutical Supply Chain

February 24, 2021

HHS Nominee Pledges To Move “Swiftly” On Drug Pricing, But No Specifics; PBMs Must Be “Kept On Their Toes”

February 23, 2021

Prevision Policy Clips | Medicaid Rebate Provision Will Stay In Senate COVID Relief Bill, Finance Chair

February 23, 2021

COVID-19 MAb Development Guidance Calls For Cooperation Among Manufacturers; FDA Suggests Surrogate Endpoints Possible For Variants

February 23, 2021

FDA Sets 10% Non-Inferiority Margins For Modified Coronavirus Vaccines As Agency Gets Ready For Variants; CBER’s Marks Details Trial Size, Length

February 23, 2021

Prevision Policy Clips | CBO Study Of Comparative Drug Prices To Federal Programs Prepared For Senate Budget Committee

February 22, 2021

Medicare “Payment Streams” For Gene/Cell Therapies: Innovation Fund, NTAPs-Plus, And Medicare Advantage Offer Reimbursement Pathways

February 19, 2021

Prevision Policy Clips | A New Beginning? Biden Visit To Pfizer COVID Vaccine Plant In Michigan

February 19, 2021

ICER Panel Finds Inadequate Evidence to Demonstrate Net Health Benefit of AZ’s Roxadustat for CKD Anemia; Meeting Comes Before FDA Approval, May Require a Follow Up

February 18, 2021

Oncology Immunotherapy Safety: Harmonized Data Collection Would Better Track CRS Risk, Friends Of Cancer Research Working Group Says

February 18, 2021

Prevision Policy Clips | FDA Defends Drug Development Collaboration With Sponsors In Response To Public Citizen Aducanumab Letter

February 18, 2021
1 2 3 4 5 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2021 Prevision Policy. All Rights Reserved. Privacy Policy